5-HT1F Agonist Toxicity Profile and Role in Paradigm
The Significance of 5-HT1F Agonist Approval
Recent Approvals for Acute Migraine
The Importance of Patient Communication
Therapy Assessment: Pain Relief & Onset Monitorization
Acute Migraine Treatment: Pain Freedom and Guidelines
Goals of and Recommended Approach for Acute Treatment
Acute Migraine Management: Overview and Unmet Needs
This Week on NeurologyLive — January 18, 2021
Here's what is coming soon to NeurologyLive.
Safety and Efficacy of CBD in Patients With TSC
NMOSD Early Age of Onset Predicts Severe Residual Vision Loss
Patients with an early age of onset (AO) were also more likely to receive less effective first-line oral therapy than those with later AOs.
William Rosenfeld, MD: Reducing Concomitant ASM Dosages for Focal Seizures
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
Raymond Sanchez, MD: Phase 2 Trial Data of Tavapadon in Parkinson Disease
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
Biogen, Apple to Initiate Study to Develop Cognitive Health Digital Biomarkers
Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.
Helius Technologies Submits FDA Response in Pursuit of PoNS De Novo Classification
The FDA previously declined to approve de novo classification in April 2019.
NeurologyLive Friday 5 — January 15, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.
Strategies for Choosing Initial Therapy in MS
Consumer Sleep Tracking Devices Perform Equally or Better Than Actigraphy
No devices performed better than polysomnography, but the researchers believe they warrant further testing.
Episode 27: Short, Sudden, Strange, Similar Spells
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jacqueline French, MD.
Cenobamate’s Efficacy in Seizure Freedom and Decreasing Concomitant Medication Use
William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.
Clinical Benefit of Fenfluramine in Dravet Syndrome
ABC/2 Method Shows Strong Accuracy in Measuring Infarct Volume
The ability of the ABC/2 method to correctly identify patients with an infarct volume below a pre-defined cut-point proved to be very high for various cut-points.
Brian Wainger, MD, PhD: Momentum Within the ALS Treatment Landscape
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.
EDSS Less Accurate Than Other Outcome Measures for Secondary Progressive MS
The EDSS inaccurately reported improvement rates while paralleling disability progression rates.
Overview of Sleep Paralysis and 'Sleep Demons'
Alicia Roth, PhD, provides a Q&A perspective on the science between 2 terrifying, sleep-related events.
P-Tau181 Associated With Longitudinal Neurodegeneration in Alzheimer Disease
The findings suggest and confirm previous studies that suggested plasma p-tau181 may be used as a measure to monitor Alzheimer disease progression in clinical practice and treatment trials.
MIND Diet Effective in Delaying Parkinson Onset in Women
Men were observed to derive benefit from a Greek Mediterranean diet and women were found to generally adhere more closely to diet interventions than men.
Leo Petrossian, PhD, MBA: Accelerating Optimization of Epilepsy Management
The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.
New AASM Guidelines Make Strong Recommendation for Behavioral Therapy in Chronic Insomnia
The new American Academy of Sleep Medicine guidelines are the first to use the GRADE system of evaluating behavioral insomnia therapies.
Experimental DMD Gene Therapy Phase 3 Trial Launched
The Pfizer candidate PF-06939926 has also received fast track, orphan drug, and rare pediatric disease designations from the FDA.
